Exagen Inc. XGN
5.04 USD -0.22 (-4.28%)
At closeNov 11, 2026, 7:59 PM EST
4.93 -0.11 -2.09%
After hours · Nov 11, 7:59 PM ET
4.69 Day range 5.64
2.59 52-week range 9.74
- YTD
- -17.19%
- 1 year
- -45.39%
News
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.
marketbeat.com What Exagen (XGN) Said on Its Q3 Earnings Call Exagen NASDAQ: XGN reported third-quarter revenue of $18.4 million, up 7% from a year earlier, as higher test volume and pricing helped the autoimmune diagnostics company post what management…
seekingalpha.com Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imaging
zacks.com Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
benzinga.com Exagen Q3 2026 Earnings Call Transcript Exagen (NASDAQ:XGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Exagen Affirms FY2026 Sales Guidance of $72.000M-$75.000M vs $73.886M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $72.000 million-$75.000 million to $72.000 million-$75.000 million vs $73.886 million estimate.- benzinga.com Exagen Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $18.417M Beat $18.343M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 31.58 percent decrease over losses of $(0.19) per…
globenewswire.com Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Exagen Inc. to Participate in Upcoming Investor Conferences Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
globenewswire.com Exagen to Announce Third Quarter Financial Results on November 10, 2026 CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30,…
defenseworld.net Exagen (NASDAQ: XGN) owner buys 14,000 shares in new insider filing What happened Exagen Inc. (NASDAQ: XGN) filed a Form 4 showing Jorey Chernett, a director and 10% owner, bought 14,000 common shares on 2026-10-19. The filing lists the trade as a purchase, and the…
defenseworld.net Exagen (NASDAQ:XGN) CEO John Aballi Sells 34,294 Shares of Stock Exagen Inc. (NASDAQ: XGN - Get Free Report) CEO John Aballi sold 34,294 shares of the company's stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a…
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.- benzinga.com TD Cowen Maintains Buy on Exagen, Raises Price Target to $11 TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
defenseworld.net Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysis Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
defenseworld.net Exagen Inc. (NASDAQ:XGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research…- benzinga.com Full Transcript: Exagen Q2 2026 Earnings Call On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive…
defenseworld.net InfuSystem (NYSE:INFU) & Exagen (NASDAQ:XGN) Head to Head Contrast Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies…
defenseworld.net Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses…
defenseworld.net Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One…
defenseworld.net Reviewing Amplifon (OTCMKTS:AMFPF) & Exagen (NASDAQ:XGN) Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
benzinga.com B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12 B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.
marketbeat.com Exagen Q2 Earnings Call Highlights Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to…
seekingalpha.com Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…
zacks.com Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
globenewswire.com Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 -…
globenewswire.com Exagen Inc. to Participate in Upcoming Investor Conference CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor…
globenewswire.com Exagen to Announce Second Quarter Financial Results on August 4, 2026 CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026,…- benzinga.com Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8 Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.
- benzinga.com Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests Alone Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markersDemonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.
benzinga.com Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 15 percent increase over losses of $(0.20) per…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $10 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $15 to $10.
- benzinga.com Craig-Hallum Maintains Buy on Exagen, Lowers Price Target to $10 Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $12 to $10.
- benzinga.com Keybanc Maintains Overweight on Exagen, Lowers Price Target to $10 Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $15 to $10.
benzinga.com 4 Analysts Have This To Say About Exagen 
benzinga.com Exagen Earnings Report: Q4 Overview 
benzinga.com Exagen Q4 EPS $(0.20) Misses $(0.18) Estimate, Sales $16.631M Beat $16.567M Estimate. Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is unchanged from the same period last year. The…- benzinga.com Earnings Scheduled For March 10, 2026
benzinga.com A Peek at Exagen's Future Earnings 
benzinga.com TD Cowen Maintains Buy on Exagen, Lowers Price Target to $10 TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $13 to $10.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8 B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.